Claim Missing Document
Check
Articles

Found 4 Documents
Search

Platelet-to-Lymphocyte Ratio as a Potential Diagnostic Marker for Acute Coronary Syndromes in Resource-Limited Settings: A Cross-Sectional Study from Single Center in Banten, Indonesia Mubarak, Thariq; Mervina Yulih Cania; Hafiz Mirza Fadrian
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 8 No. 12 (2024): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v8i12.1147

Abstract

Background: Acute coronary syndrome (ACS) poses a significant global health burden, particularly in resource-limited settings where access to advanced diagnostic tools is often constrained. The platelet-to-lymphocyte ratio (PLR), a simple and readily available marker from routine blood tests, has shown promise as a potential diagnostic tool for ACS. This study aimed to evaluate the diagnostic accuracy of PLR in identifying ACS patients in a resource-limited setting in Indonesia. Methods: A cross-sectional study was conducted at Hermina Periuk Hospital, Tangerang, Banten, Indonesia, between December 2020 and December 2022. Patients presenting to the Emergency Room with a diagnosis of ACS were included. PLR was calculated from complete blood count data, and cardiac troponin I (cTnI) served as the gold standard for ACS diagnosis. The diagnostic performance of PLR in predicting elevated cTnI levels was assessed. Results: Of the 121 patients initially identified, 39 met the inclusion and exclusion criteria. Elevated PLR values (>116) were observed in 25 patients (64.1%), while 15 patients (38.5%) had elevated cTnI levels. A statistically significant correlation was found between elevated PLR and elevated cTnI (p = 0.018). No significant association was observed between neutrophil-to-lymphocyte ratio (NLR) and elevated cTnI. Conclusion: PLR demonstrates potential as a diagnostic marker for ACS in resource-limited settings. Its simplicity, accessibility, and cost-effectiveness make it a valuable tool for early identification and risk stratification of ACS patients, particularly in areas with limited access to advanced cardiac diagnostics.
Prostate-Specific Antigen (PSA) as a Predictor of Prostate Cancer on Transrectal Biopsy: A Meta-Analysis Arief Aulia; Hafiz Mirza Fadrian
Open Access Indonesian Journal of Medical Reviews Vol. 4 No. 5 (2024): Open Access Indonesian Journal of Medical Reviews
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/oaijmr.v4i5.650

Abstract

Prostate cancer is a leading cause of cancer-related death in men globally. Early detection is critical for improving patient outcomes. Prostate-specific antigen (PSA) testing is a widely used screening tool, but its accuracy in predicting prostate cancer on transrectal biopsy remains a topic of debate. This meta-analysis aims to evaluate the diagnostic accuracy of PSA in predicting prostate cancer on transrectal biopsy. A systematic search of electronic databases (PubMed, Scopus, Web of Science) was conducted to identify relevant studies published between 2013 and 2024. Studies reporting the sensitivity, specificity, and area under the receiver operating characteristic curve (AUC) of PSA for predicting prostate cancer on transrectal biopsy were included. Data were extracted, and the pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR) were calculated using a random-effects model. Six studies met the inclusion criteria, comprising a total of 1,245 patients. The pooled sensitivity and specificity of PSA for predicting prostate cancer on transrectal biopsy were 0.77 (95% CI, 0.75 - 0.82) and 0.68 (95% CI, 0.62-0.73), respectively. The pooled PLR, NLR, and DOR were 3.27 (95% CI, 2.45-4.37), 0.20 (95% CI, 0.14-0.28), and 16.39 (95% CI, 10.27-26.21), respectively. The pooled AUC was 0.87 (95% CI, 0.84-0.90). In conclusion, PSA demonstrates good diagnostic accuracy in predicting prostate cancer on transrectal biopsy. However, it is essential to consider its limitations, including false positives and negatives. Further research is needed to identify strategies to improve the accuracy of PSA testing and reduce unnecessary biopsies.
Histopathological Heterogeneity in Upper Tract Urothelial Carcinoma and Bladder: A Systematic Review Hafiz Mirza Fadrian; Arif Aulia; Kautsarrahman
Open Access Indonesian Journal of Medical Reviews Vol. 4 No. 5 (2024): Open Access Indonesian Journal of Medical Reviews
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/oaijmr.v4i5.651

Abstract

Upper tract urothelial carcinoma (UTUC) and bladder is a rare malignancy with varied histopathological features that influence treatment strategies and patient outcomes. This systematic review comprehensively analyzes the histopathological heterogeneity of UTUC and bladder, focusing on its impact on diagnosis, prognosis, and therapeutic implications. A systematic search of PubMed, Google Scholar, NCBI, and ScienceDirect was conducted to identify relevant studies published in the last 20 years. Articles were included if they focused on the histopathological characterization of UTUC and bladder. A total of 10 studies were included in the review. Histopathological analysis revealed diverse subtypes, including papillary, micropapillary, nested, plasmacytoid, and sarcomatoid variants, each with distinct features and prognostic implications. In conclusion, UTUC and bladder exhibits significant histopathological heterogeneity, which influences tumor behavior and patient outcomes. Integrating histopathological evaluation with molecular profiling can refine risk stratification and guide personalized treatment decisions. Further research is needed to elucidate the complex interplay of these factors and develop targeted therapies for improved management of UTUC and bladder.
Platelet-to-Lymphocyte Ratio as a Potential Diagnostic Marker for Acute Coronary Syndromes in Resource-Limited Settings: A Cross-Sectional Study from Single Center in Banten, Indonesia Mubarak, Thariq; Mervina Yulih Cania; Hafiz Mirza Fadrian
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 8 No. 12 (2024): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v8i12.1147

Abstract

Background: Acute coronary syndrome (ACS) poses a significant global health burden, particularly in resource-limited settings where access to advanced diagnostic tools is often constrained. The platelet-to-lymphocyte ratio (PLR), a simple and readily available marker from routine blood tests, has shown promise as a potential diagnostic tool for ACS. This study aimed to evaluate the diagnostic accuracy of PLR in identifying ACS patients in a resource-limited setting in Indonesia. Methods: A cross-sectional study was conducted at Hermina Periuk Hospital, Tangerang, Banten, Indonesia, between December 2020 and December 2022. Patients presenting to the Emergency Room with a diagnosis of ACS were included. PLR was calculated from complete blood count data, and cardiac troponin I (cTnI) served as the gold standard for ACS diagnosis. The diagnostic performance of PLR in predicting elevated cTnI levels was assessed. Results: Of the 121 patients initially identified, 39 met the inclusion and exclusion criteria. Elevated PLR values (>116) were observed in 25 patients (64.1%), while 15 patients (38.5%) had elevated cTnI levels. A statistically significant correlation was found between elevated PLR and elevated cTnI (p = 0.018). No significant association was observed between neutrophil-to-lymphocyte ratio (NLR) and elevated cTnI. Conclusion: PLR demonstrates potential as a diagnostic marker for ACS in resource-limited settings. Its simplicity, accessibility, and cost-effectiveness make it a valuable tool for early identification and risk stratification of ACS patients, particularly in areas with limited access to advanced cardiac diagnostics.